Singapore infrastructure a draw for pharma giants
Pharmaceutical firm AbbVie has invested S$400 million to open a manufacturing plant at Tuas Biomedical Park, to support its global manufacturing pipeline.
Add BT as a preferred source
IN 50 YEARS, Singapore has undergone significant transformation from a developing country into a thriving metropolis. Today, with its robust physical and regulatory environment, global connectivity and skilled talent pool, this city-state is a multidisciplinary hub for businesses looking to access emerging market opportunities across the region.
The nation's strong foundation in research and development (R&D) has drawn significant investments from research institutes and biopharmaceutical companies. In the span of a decade from 2005 to 2015, we have seen a 30 per cent increase in the number of clinical research programmes conducted in Singapore.
As more companies embark on drug discovery and translational clinical research in Singapore, the implications on its manufacturing output cannot be overlooked. Today, six out of the top 10 drugs globally are made in Singapore.
Copyright SPH Media. All rights reserved.
